XNAS
ACET
Market cap57mUSD
Oct 08, Last price
5.74USD
1D
-7.12%
1Q
-34.99%
IPO
-99.68%
Name
Adicet Bio Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
72.02%
Rev. gr., 5y
-46.28%
Revenues
0
Net income
-117m
L-0.27%
CFO
-95m
L+3.10%
Dividend
Sep 21, 20180.0001 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Adicet Bio, Inc., a pioneering biotechnology firm, is dedicated to the discovery and development of "off-the-shelf" gamma delta T cell therapies aimed at combating cancer and other illnesses. Their innovative approach involves genetically modifying gamma delta T cells by integrating both chimeric antigen receptors (CARs) and T-cell receptor-mimicking antibodies. This proprietary engineering is designed to achieve highly selective tumor targeting, bolster both innate and adaptive anti-tumor immune responses, and enhance cell persistence for durable therapeutic outcomes in patients. Their lead therapeutic candidate, ADI-001, is currently progressing through Phase I clinical trials as a potential treatment for non-Hodgkin's lymphoma. Furthermore, their pipeline includes ADI-002, currently undergoing preclinical studies for various solid tumors. The company operates out of Boston, Massachusetts.
Key people
Lloyd Klickstein
Chief Scientific Officer · since 2019
Joan Mannick
Chief Medical Officer · since 2017
Meredith S. Manning
Chief Commercial Officer · since 2018
Susan Stewart
Head of Regulatory Affairs
Independent Director · since 2018
Independent Director · since 2017
Michael J. Grissinger
Independent Director · since 2018
David Steinberg
Independent Director · since 2017
Independent Director · since 2017
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
501 Boylston Street
Suite 6102
Boston, MA 02116
US
Suite 6102
Boston, MA 02116
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||